Merck reported a net loss of $5,575 million for the first half of 2026, a reversal from a $9,506 million profit in the same period of 2025, driven by a $12,592 million surge in first-quarter research and development spending that the company has not explained in forward guidance. Sales grew 5 percent to $32,893 million in the first half, but the operating loss and the absence of any revised full-year outlook leave the trajectory for the back half of 2026 entirely opaque.
The numbers
Second-quarter sales of $16,607 million grew 5 percent from $15,806 million in the prior year, a modest acceleration. But the first quarter tells a different story: R&D spending jumped to $12,592 million from $3,621 million in the first quarter of 2025, a 248 percent increase that consumed operating margin entirely. The company reported a loss before taxes of $3,534 million in 1Q 2026 versus income before taxes of $5,903 million in 1Q 2025. For the first six months combined, income before taxes fell to a loss of $4,217 million from $10,902 million.
The company has not issued revised full-year 2026 guidance in this filing. The document projects full-year 2026 sales of $65,011 million (5 percent growth) and full-year net income attributable to Merck of $18,254 million, but these are mathematical sums of reported quarters and forward assumptions for 3Q and 4Q that remain unstated. No guidance revision, raise, cut, or affirmation appears in the filing.
What it means
The first-quarter R&D spike is the operative fact, but the filing provides no narrative explanation for it. The company does not disclose whether this represents a one-time charge related to a failed program, an acceleration of milestone payments on an acquisition, a change in capitalization policy, or a structural increase in research intensity. Cost of sales as a percentage of revenue rose to 26 percent in the first half of 2026 from 22 percent in the first half of 2025, suggesting either manufacturing inefficiency, unfavorable product mix, or pricing pressure, but the filing does not isolate the driver. Restructuring costs fell 73 percent in the second quarter to $151 million from $560 million in the prior year, which is a tailwind, but it is too small to offset the R&D headwind.
The second quarter itself shows stabilization: R&D spending of $9,741 million is elevated versus the $4,048 million in 2Q 2025, but the company achieved a $683 million loss before taxes rather than the $3,534 million loss in 1Q. This suggests the first quarter was the anomaly, not a new baseline. However, without forward guidance, investors cannot determine whether the company expects 3Q and 4Q R&D to revert to historical levels (around $4 billion per quarter) or remain elevated. If the elevated run rate persists, full-year net income of $18,254 million is unachievable; if it reverts, the projection holds.
The filing also leaves unresolved whether the 5 percent sales growth is sustainable or a comparison artifact. The company does not break out growth by therapeutic area or geography, so it is impossible to test whether the growth is broad-based or concentrated in a single franchise. The non-GAAP reconciliation for 2Q 2025 shows $5,366 million in adjusted earnings per share, but no 2026 non-GAAP reconciliation is provided, making it difficult to assess underlying operational performance stripped of one-time items.
What to watch
The next disclosure point is the third-quarter 2026 earnings release, expected in October or November 2026, where the company will either confirm that first-quarter R&D was an outlier or reveal that elevated spending is structural. Any revision to full-year guidance at that time will answer whether the first-half loss was a temporary trough or a signal of margin compression ahead.
Source: the company’s 8-K filed 2026-08-04 with the SEC.
For the standing yardsticks on Merck & Co: the price tag, the filed record, and the four gauges, refreshed with each edition, see the BullScope Evidence Sheet: Merck & Co.
